13/ Thus, while developing treatments for rare diseases is actually significantly cheaper than non-rare diseases, the current model has created a gap in funding. https://t.co/k0k5h7n3uj
223 followers
2,813 followers
Regulatory bodies make it unlikely that companies will risk their capital to save your life if you have a rare disease. "Orphan" drugs have an expedited process, but the average cost is still $166M vs $291M, so drug market size still weighs heavily. https
413 followers
#RT @aHUSAllianceAct: Interesting article w/ #RareDiseaseDay approaching 28 Feb 2021 - "We found that the out-of-pocket clinical costs per approved #orphandrug to be $166 million and $291 million (2013 USD) per non-orphan #drug." #clinicaltrial #pharma htt
2,973 followers
RT @aHUSAllianceAct: Interesting article w/ #RareDiseaseDay approaching 28 Feb 2021 - "We found that the out-of-pocket clinical costs per a…